Validation of the Oncomine™ Focus Panel for Next Generation Sequencing of clinical tumour samples

Hannah L. Williams, Kathy Walsh, Austin Diamond, Anca Oniscu, Zandra C. Deans

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)


The clinical utility of next-generation sequencing (NGS) for a diverse range of targets is expanding, increasing the need for multiplexed analysis of both DNA and RNA. However, translation into daily use requires a rigorous and comprehensive validation strategy. The aim of this clinical validation was to assess the performance of the Ion Torrent Personal Genome Machine (IonPGM™) and validate the Oncomine™ Focus DNA and RNA Fusion panels for clinical application in solid tumour testing of formalin-fixed, paraffin-embedded (FFPE) tissue. Using a mixture of routine FFPE and reference material across a variety of tissue and specimen types, we sequenced 86 and 31 samples on the Oncomine™ Focus DNA and RNA Fusion assays, respectively. This validation considered a number of parameters including the clinical robustness of the bioinformatics pipeline for variant detection and interpretation. The Oncomine™ Focus DNA assay had a sample and variant-based sensitivity of 99.1 and 97.1%, respectively, and an assay specificity of 100%. The Oncomine™ Focus Fusion panel had a good sensitivity and specificity based upon the samples assessed, however requires further validation to confirm findings due to limited sample numbers. We observed a good sequencing performance based upon amplicon, gene (hotspot variants within gene) and sample specific analysis with 92% of clinical samples obtaining an average amplicon coverage above 500X. Detection of some indels was challenging for the routine IonReporter™ workflow; however, the addition of NextGENe® software improved indel identification demonstrating the importance of both bench and bioinformatic validation. With an increasing number of clinically actionable targets requiring a variety of methodologies, NGS provides a cost-effective and time-saving methodology to assess multiple targets across different modalities. We suggest the use of multiple analysis software to ensure identification of clinically applicable variants.
Original languageEnglish
Number of pages15
JournalVirchows Archiv
VolumeFirst Online
Early online date13 Aug 2018
Publication statusE-pub ahead of print - 13 Aug 2018


  • Next-generation sequencing
  • Molecular pathology
  • Clinical validation
  • FFPE


Dive into the research topics of 'Validation of the Oncomine™ Focus Panel for Next Generation Sequencing of clinical tumour samples'. Together they form a unique fingerprint.

Cite this